# CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).

> **NCT06078306** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 20 (estimated)

## Conditions studied

- B Acute Lymphoblastic Leukemia
- Ph-Negative ALL
- High Risk Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Azacitidine Injection
- **DRUG:** Venetoclax
- **DRUG:** CD19CD22 CAR-T

## Key facts

- **NCT ID:** NCT06078306
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04-20
- **Primary completion:** 2024-09-10
- **Final completion:** 2025-09-10
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06078306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06078306, "CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06078306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*